Astegolimab
Astegolimab is an IgG2 mAb that blocks IL-33 signaling by targeting ST2,
the IL-33 receptor 96.
The phase 2b ZENYATTA study191 evaluated the
safety and efficacy of astegolimab in patients with severe asthma.
Astegolimab was safe, well tolerated, and effective in reducing the
annualized asthma exacerbations at week 54. Astegolimab did not show a
significant benefit compared to placebo in the absolute change in
FEV1 at week 54.